Global PCSK9 Inhibitors Market is expected to grow at a 15.0% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Low-density lipoprotein (LDL) receptor degradation is controlled by the proprotein convertase subtilisin/Kexin type 9 serine protease (PCSK9), which reduces the clearance of circulating LDL particles. PCSK9 inhibitors have been developed as a consequence of controlling PSCK9 levels. LDL clearance from the blood is inhibited by PCSK9's attachment to low-density lipoprotein receptors (LDLRs), which causes blood levels of LDL to increase. The PCSK9 enzyme is now inhibited with the use of a PCSK9 inhibitor, which increases the number of LDL receptors that can remove LDL from circulation.
Due to a number of factors, comprising an increase in global healthcare spending, a rise in statin resistance among patients with familial hypercholesterolemia, an increase in the risk of cardiovascular diseases like myocardial infarction and coronary revascularization, etc., the PCSK9 Inhibitors market dynamics are anticipated to change in the upcoming years. The market for PCSK9 Inhibitors will grow significantly if PCSK9 inhibition is used as a preventative approach to reduce the burden of CVD. The market for PCSK9 inhibitors is also expected to expand due to the effects of these drugs in new therapeutic fields.
Despite the fact that monoclonal antibodies have shown to be the most therapeutically effective PCSK9 inhibitors, additional novel medications are now undergoing various phases of research and will soon be on the market for PCSK9 inhibitors.
The PCSK9 Inhibitors Market is segmented based on Drug, Modality, Indication and Sales Channel. The Drug Segment comprises Alirocumab, Evolocumab, Inclisiran, Pipeline Drugs (Ebronucimab, Tafolecimab, Lerodalcibep, Others (MK-0616, etc))). The Modality segment includes Fully-humanized monoclonal antibodies, siRNA. The Indication segment categorises into Primary Hyperlipidemia, Familial Hyper Cholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD), and Prevention of Other Cardiovascular Events. By Sales Channel, the market is segmented into Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies.
North America is likely to account for a substantial portion of the global PCSK9 inhibitors market during the forecast period because of the presence of well-established enterprises producing and marketing PCSK9 inhibitors. According to the US Department of Health and Human Services, around 805,000 Americans have a heart attack each year. This highlights the importance of medications like PCSK9 inhibitors in lowering cholesterol and preventing heart disease at an early stage. The region's high prevalence of cardiovascular illnesses, combined with new product releases, will drive PCSK9 inhibitor growth in the region. Furthermore, expanding R&D activities and increased awareness and prevalence of risk factors such as diabetes in the general population are expected to drive the North American market during the forecast period.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 15.0% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn, and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug, Modality, Indication and Sales Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca, Affiris, BMS, Ionis Pharmaceuticals, Cyon Therapeutics, and Daiichi Sankyo |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global PCSK9 Inhibitor Market Snapshot
Chapter 4. Global PCSK9 Inhibitor Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2021-2034
4.8. Global PCSK9 Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2021)
4.10. Use/impact of AI on PCSK9 Inhibitor Market Industry Trends
Chapter 5. PCSK9 Inhibitor Market Segmentation 1: By Drug, Estimates & Trend Analysis
5.1. Market Share by Drug, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug:
5.2.1. Alirocumab
5.2.2. Evolocumab
5.2.3. Inclisiran
5.2.4. Pipeline Drugs
5.2.4.1. Ebronucimab
5.2.4.2. Tafolecimab
5.2.4.3. Lerodalcibep
5.2.4.4. MK-0616
Chapter 6. PCSK9 Inhibitor Market Segmentation 2: By Modality, Estimates & Trend Analysis
6.1. Market Share by Modality, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Modality:
6.2.1. Fully-humanized Monoclonal Antibodies
6.2.2. siRNA
Chapter 7. PCSK9 Inhibitor Market Segmentation 3: By Indication, Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Primary Hyperlipidemia
7.2.2. Familial Hyper Cholesterolemia
7.2.3. Atherosclerotic Cardiovascular Disease (ASCVD)
7.2.4. Prevention of Other Cardiovascular Events
Chapter 8. PCSK9 Inhibitor Market Segmentation 4: By Sales Channel, Estimates & Trend Analysis
8.1. Market Share by Sales Channel, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Sales Channel:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Retail Pharmacies
8.2.4. Online Pharmacies
Chapter 9. PCSK9 Inhibitor Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global PCSK9 Inhibitor Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.2.3. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.2.4. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.2.5. North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.3. Europe
9.3.1. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.2. Germany
9.3.3. U.K.
9.3.4. France
9.3.5. Italy
9.3.6. Spain
9.3.7. Rest of Europe
9.3.8. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.3.9. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.3.10. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.3.11. Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.2. India
9.4.3. China
9.4.4. Japan
9.4.5. Australia
9.4.6. South Korea
9.4.7. Hong Kong
9.4.8. Southeast Asia
9.4.9. Rest of Asia Pacific
9.4.10. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.4.11. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.4.12. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.4.13. Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.5. Latin America
9.5.1. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.2. Brazil
9.5.3. Mexico
9.5.4. Rest of Latin America
9.5.5. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.5.6. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.5.7. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.5.8. Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.6.2. GCC Countries
9.6.3. Israel
9.6.4. South Africa
9.6.5. Rest of Middle East and Africa
9.6.6. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034
9.6.7. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034
9.6.8. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.6.9. Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Regeneron Pharmaceuticals, Inc. (Sanofi)
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Amgen Inc.
10.2.3. Novartis AG
10.2.4. Innovent
10.2.5. CiVi Biopharma
10.2.6. LIB Therapeutics, LLC
10.2.7. Akeso Pharmaceuticals Inc.
10.2.8. Shanghai Junshi Biosciences Co., Ltd
10.2.9. Merck & Co., Inc.
10.2.10. AstraZeneca
10.2.11. Alnylam
10.2.12. Affiris
10.2.13. BMS
10.2.14. Ionis Pharmaceuticals
10.2.15. Cyon Therapeutics
10.2.16. Daiichi Sankyo
10.2.17. Other Market Players
PCSK9 Inhibitors Market By Drug
PCSK9 Inhibitors MarketBy Modality
PCSK9 Inhibitors MarketBy Indication
PCSK9 Inhibitors MarketBy Sales Channel
PCSK9 Inhibitors Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
